Viking Therapeutics, Inc.VKTX
Price (close)
$36.75
Market cap
$4.3B
P/E
—
Revenue (TTM)
$0
Net income
-$534.8M
Dividend yield
—
1-year total return
46.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Viking Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
More on VKTX.
- Viking Therapeutics, Inc. summary
- Viking Therapeutics, Inc. financial statements
- Viking Therapeutics, Inc. key metrics
- Viking Therapeutics, Inc. health scores and style box
- Viking Therapeutics, Inc. earnings
- Viking Therapeutics, Inc. dividends
- Viking Therapeutics, Inc. valuation
- Viking Therapeutics, Inc. ownership and insiders
- Viking Therapeutics, Inc. peers
Figures from Viking Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.